GLMD - galmedpharma.com Sales Growth YoY (TTM)

Developing therapies for chronic liver pathologies with lifelong demand creates a foundation for stable revenues, allowing Galmed Pharmaceuticals to fully outsource molecule synthesis to external CRO contractors. The rolling 12-month sales growth rate compared to the same period last year confirms this capital mobility, with the indicator reaching 0.00. Diversification into the fatty liver disease segment completes the strategy, providing access to untapped market niches.
galmedpharma.com (GLMD) - metric breakdowns and financial figures

Selecting high-quality issuers requires verifying business scaling rates through a cash flow stability filter. This chart of 12-month YoY sales changes filters out speculative noise by measuring real revenue dynamics, which is critical for Galmed Pharmaceuticals (GLMD) due to the outsourcing of molecule development and synthesis, allowing the company to minimize capital expenditures and assess the commercial efficiency of its model through the lens of this indicator.